Patient Enrollment Equipment & Supplies
49 equipment items found
Manufactured by:Veracyte, Inc. based inSouth San Francisco, CALIFORNIA (USA)
LymphMark (Lymphoma) – We are developing this lymphoma subtyping test as a companion diagnostic for Acerta Pharma and AstraZeneca’s acalabrutinib (Calquence®). In April 2021, we announced that the first patient has been enrolled and randomized in Acerta Pharma’s Phase 3 ESCALADE trial, which uses the investigational LymphMark test to identify patients with untreated diffuse ...
Manufactured by:Longenesis based inRiga, LATVIA
Collect Real World Data and patient outcomes; Longenesis.Engage is a digital patient engagement platform that enables the benefits of digital approach to patient engagement and research execution. Conduct multiple research projects, funnel patient cohorts for upcoming studies, follow-up and re-engage the participants, and manage their consent while upholding the data protection regulations and ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
Bristol Myers Squibb is enrolling patients in the dose escalation phase of a Phase 1/2a clinical trial (NCT03994601) of a second anti-CTLA-4 Probody, BMS-986288, based on a modified version of Yervoy® (ipilimumab), to evaluate a CTLA-4-directed Probody therapeutic alone or in combination with Opdivo® (nivolumab) in patients with selected advanced solid cancers. CTLA-4, a clinically ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
Built on the foundation of Specificity Enhanced Bi-specific Antibody (SEBA) molecules the SEBA-ADC have an advanced mechanism of action. This advanced functional class is referred to as Heterogeneity overcoming - Immunogenic death inducing - Resistance antagonizing - Enhanced Specificity (HIRE) molecules that target cancer cells. While HIRE molecules provide cancer cells specific targeting, and ...
by:Abivax based inParis, FRANCE
ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in the completed Phase 2a and Phase 2b induction studies as well as in ongoing long-term maintenance studies in patients with moderate-to-severe ulcerative colitis (UC).Due to the clinical similarities of Crohn’s disease (CD) and UC, and the predictability of the DSS model ...
Manufactured by:Biocartis NV based inMechelen, BELGIUM
The fully automated Idylla ctKRAS Mutation Test is minimally invasive, fast and easy to perform and can be used as complement to tissue testing to determine the RAS mutation status at diagnosis. IdyllaTM ctKRAS covers 21 KRAS mutations in exons 2,3 and 4 and showed an high concordance to NGS of 96% using plasma samples from 198 mCRC patients enrolled in the prospective multicenter RASANC ...
Manufactured by:atHeart Medical based inBaar, SWITZERLAND
Defects vary in size. Some may close on their own early in life, while others require an intervention. Today, the vast majority are performed through minimally invasive catheter-based interventions. They consist in implanting an atrial septal occluder through a transcatheter procedure to close the defect. Current ASD occluder devices have dense metal frames that permanently clamp the septum. The ...
Manufactured by:AOBiome Therapeutic, LLC based inCambridge, MASSACHUSETTS (USA)
We have completed six Phase 2 clinical programs and multiple pre-clinical programs. Over 1,000 patients have been enrolled in our clinical trials since 2016. All of those patients except for 28 in our open label pediatric study have been enrolled in randomized double-blind placebo controlled clinical trials evaluating both topical and intranasal routes of delivery of AOB with treatment durations ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
SL-801 is a structurally novel, oral, small molecule, reversible inhibitor of exportin-1 (XPO1), a nuclear transport protein implicated in both solid tumors and hematologic malignancies. SL-801 has demonstrated preclinical in vitro and in vivo antitumor activity against a wide array of solid and hematologic cancers. SL-801’s potential ability to reversibly bind XPO1 may offer the ...
Manufactured by:Nkarta, Inc. based inSouth San Francisco, CALIFORNIA (USA)
OX40 costimulatory domain, CD3ζ signaling moiety, membrane bound ...
Manufactured by:Sense Neuro Diagnostics based inCincinnati, OHIO (USA)
Sense is developing non-invasive brain scanners that enable faster detection and triage, and continuous monitoring of brain injury, to improve patient ...
by:Castle Biosciences, Inc. based inFriendswood, TEXAS (USA)
Our DecisionDx-CMSeq is a 3-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to cutaneous melanoma in melanoma tumor tissue. The test includes hotspot mutations in the genes BRAF, NRAS and ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
This Specificity Enhanced Bi-specific Antibody (SEBA) is of the oncology therapeutic class that bind functional proteins on the surface of cells, in this molecule to block growth signals that cancer cells depend on for survival. The SEBA technology allows the molecule to use one surface protein for specific targeting of the cancer, and a then block a second protein, even if it is not specific ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
By combining bi-valency with bi-specificity in the tetravalent format, the dual checkpoint molecule utilizes avidity and bi-specificity to improve anti-cancer immune cell function. The specificity enhancement both synergistically enhance and expand the breadth of immune cell activity that is diminished in cancer patients (SEBA). The spatio-temporal control of bi-specificity ensure that ...
Manufactured by:Rebiotix Inc., a Ferring Company based inRoseville, MINNESOTA (USA)
Rebiotix Inc., a Ferring Company, has conducted several trials of the lead microbiota-based product in the MRT drug platform, RBX2660, for reducing the rate of recurrence of Clostridioides difficile infection. RBX2660 is currently under study in a Phase 3 clinical trial in conjunction with the US Food and Drug Administration’s Investigational New Drug ...
Manufactured by:Seres Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
SER-109 is a first-in-class investigational microbiome therapeutic administered orally following antibiotics to reduce recurrence of C. difficile infection (CDI) in patients with recurrent ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic payload. This advanced functional class is referred to ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic payload. This advanced functional class is referred to ...
Manufactured by:Lineage Cell Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
On December 20, 2021, Lineage announced that it has entered into an exclusive worldwide collaboration and license agreement with Roche and Genentech, a member of the Roche Group, for the development and commercialization of OpRegen for the treatment of ocular disorders, including advanced dry age-related macular degeneration (dry AMD) with geographic atrophy (GA) in a transaction worth up to $670 ...
Manufactured by:Galapagos NV based inMechelen, BELGIUM
Filgotinib, a preferential JAK1 inhibitor, is marketed as Jyseleca in the European Union (incl. Norway), Great Britain, and Japan for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs ...